Last reviewed · How we verify
Group S+T
This drug targets the S1P receptor to modulate lymphocyte trafficking and reduce inflammation.
This drug targets the S1P receptor to modulate lymphocyte trafficking and reduce inflammation. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.
At a glance
| Generic name | Group S+T |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
By binding to the S1P receptor, this drug inhibits lymphocyte egress from lymphoid organs, leading to a reduction in inflammation and immune response.
Approved indications
- Relapsing forms of multiple sclerosis
- Primary progressive multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Infections
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Improving Care Through Azithromycin Research for Infants in Africa (PHASE3)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (PHASE1)
- In-plane Versus Real Time Bi-plane Single-operator Laser-assisted With a Innovative T-shaped Probe for Ultrasound-guided Internal Jugular Vein Catheterization:A Randomized Controlled Trial (NA)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group S+T CI brief — competitive landscape report
- Group S+T updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI